 
Title: Open Label Extension (OLE) Study of the Safety and 
Clinical Utility of IPX203 in PD Patients with Motor Fluctuations 
Date: November 26, 2018 [STUDY_ID_REMOVED] 
 
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
Page 1 of 112 IPX203 (CARBIDOPA-LEVODOPA)  
EXTENDED-RELEASE CAPSULES  
IPX203-B16-03 
AN OPEN-LABEL EXTENSION STUDY OF THE 
SAFETY AND CLINICAL UTILITY OF IPX203 IN 
PARKINSON’S DISEASE PATIENTS WITH MOTOR 
FLUCTUATIONS  
SPONSOR  
I
mpax Laboratories, LLC  
400 Crossing Boulevard, Third Floor 
Bridgewater , NJ 08807-2863 
Orig
inal Protocol, 25 April  2018 
Amendment 1, 22 June 2018 
Amendment 2, 26 November 2018 
CONFIDE
NTIALITY STATEMENT  
All information provided is the property of Impax Laboratories, LLC  and may not be divulged, 
published or otherwise disclosed without written consent of Impax.  All information provided to 
the Investigator by the Sponsor, including clinical observations at  the investigative site, shall be 
held strictly confidential and confined to the clinical personnel involved in conducting the study, under the supervision of the Investigator.  This includes but is not limited to preclinical data, protocols, case report forms, and verbal or written communications.  This information may be 
related in confidence to the Institutional Review Board or other committees functioning in a 
similar capacity.  All reports, subject samples, data published or submitted to third parties will be identified by a coded number and initials only in order to maintain subject confidentiality. 
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 3 of 112 INVESTIGATOR’S AGREEMENT  
 
Protocol No.:  IPX203- B16-03 
Protocol Title:  An Open -Label Extension Study of the Safety and Clinical Utility of IPX203 
in Parkinson’s Disease Patients with Motor Fluctuations 
 
 I have read this protocol and agree to conduct the study as outlined herein, complying with the 
obligations and requirements of clinical investigators and all other requirements of International 
Conference on Harmonization (ICH), Good Clinical Practice (GCP), and the appropriate regulatory authority. 
I will provide copies of the protocol and all pertinent information to all individuals responsible to 
me who assist in the conduct of this clinical study.  I will discuss this material with them to ensure that they are fully informed regarding the study medication, the conduct of the study, and 
the obligations of confidentiality.  
 
 
_________________________________________ ___________________ 
Principal Investigator’s signature  Date  
 
 
_________________________________________ Principal Investigator’s printed name  
  
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 4 of 112 STUDY C ONTACT  INFORMATION 
Changes in Impax study personnel listed on this page do not require a protocol amendment. 
Role  Name and Contact Information 
Sponsor Impax Laboratories, LLC  
400 Crossing Boulevard, Third Floor 
Bridgewater , NJ 08807-2863 
(732) 595-4600 
Serious Adverse Event Reporting FAX:  (866) 954-2057 

Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 5 of 112 1. SYNOPSIS  
Name of Sponsor/Company: Impax Laboratories, LLC (Impax)  
Name of Investigational Product: IPX203 (carbidopa-levodopa) Extended- Release Capsules  
Name of Active Ingredient s: carbidopa (CD), levodopa (LD) 
Protocol Title: An Open -Label Extension Study of the Safety and Clinical Utility of IPX203 
in Parkinson’s Disease Patients with Motor Fluctuations  
Protocol No.:   IPX203- B16-03 
Study center(s):   Multicenter  
Phase of Development:   Phase 3 
Objectives:   To evaluate the long- term safety and clinical utility of IPX203 in the treatment 
of subjects  with advanced Parkinson’s disease (PD) who have motor fluctuations. 
Methodology:   This is a 9 -month, multicenter open- label safety extension study.  Subjects 
who have successfully completed Study IPX203-B16-02 (A Randomized Controlled Study to 
Compare the Safety and Efficacy of IPX203 with  Immediate -Release Carbidopa-Levodopa in 
Parkinson’s Disease Patients with Motor Fluctuations) may have the opportunity to enr oll in 
this open- label study.  This study will consist of a baseline visit (Visit 1) followed by 3  visits 
(Visits 2 to 4) spaced at approximately 3-month intervals.  For subjects who successfully 
complete Study IPX203- B16-02, t he baseline visit (Visit 1) of this study will occur  coincident 
with the End of Study (E OS) Visit 7 of the preceding study.  After providing written informed 
consent (and signing Health Insurance Portability and Accountability Act [ HIPAA ] 
authorization for subjects at United States [US]  sites only) , confirmation of eligibility and 
baseline procedures will be performed.  Subjects will be initially started on the final IPX203 dosing regimen that was determined during the IPX203 dose conversion period of Study IPX203- B16-02.  Investigat ors are permitted to adjust the dosing regimen of IPX203 during 
this study to achieve the optimal balance of efficacy and safety and any changes will be 
recorded.  
Subjects may continue to take their non- LD-containing PD concomitant medications 
(including dopamine agonists, amantadine, and selective monoamine oxidase- B (MAO- B) 
inhibitors [ safinamide, rasagiline and selegiline]) during the study.  Changes in doses or in 
dosing regimens of all non- CD-LD PD medications and/or the addition of new non- CD-LD 
PD medications will be captured.   Supplemental CD  and benserazide, apomorphine, and the 
addition of catechol -O-methyltransferase ( COMT ) inhibitors (eg, entacapone, opicapone, and 
tolcapone) can be initiated during this study.  
Adverse events  (AEs), supine and standing orthostatic vital signs, and concomitant 
medications will be evaluated throughout the course of the study.  Electrocardiograms (ECGs), clinical laboratory tests, physical examinations, and the Columbia -Suicide Severity Rating 
Scale (C -SSRS) will also be performed.  The following clinical utility measures will be 
assessed:  Patient Global Impression  of Severity ( PGI-S), Clinician Global Impression  of 
Severity (CGI -S), Treatment Satisfaction Assessment (TSA), Parkinson’s Disease Sleep Scale -
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 6 of 112 2 (PDSS -2), the 39 -item Parkinson’s Disease Questionnaire (PDQ -39), Parkinson Anxiety 
Scale (PAS), Non -Motor Symptom assessment scale (NMSS) for Parkinson’s disease, 
Gastroparesis Cardinal Symptom Index (GCSI), The Movement Disorder Society Unified 
Parkinson’s Dise ase Rating Scale (MDS -UPDRS) Parts  I to IV , 12-Item Zarit Burden 
Interview (ZBI-12) , and Early Morning Symptoms Questionnaire (E MSQ) .  Visit 4 is the end 
of study visit (EOS).  
Number of subjects (planned):  Subjects who successfully complete IPX203- B16-02 will be 
eligible to enroll in this open- label extension ( OLE) study; it is estimated that approximately 
300 subjects  will enroll.  
Diagnosis and main criteria for inclusion: 
Inclusion Criteria  
• Successfully completed Study IPX203- B16-02. 
• Able to provide written informed consent prior to the conduct of any study- specific 
procedures. 
• Female subjects of childbearing potential must have a negative urine pregnancy test at 
the baseline visit (Visit 1).  
• Agrees to use a medically acceptable method of contraception throughout the study and 
for 6 weeks after completing the study. 
Exclusion Criteria  
• Intends to use any doses of Rytary® or Duopa™ during this study. 
• Plans to use an investigational treatment other than IPX203 during the course of this 
study. 
• Neurosurgical ablation treatment for PD is planned or anticipated during the study period.  Implantation of a deep brain stimulator (DBS) for the treatment of PD is 
permitted during this study.  
• Subjects who, in the opinion of the clinical investigator, should not participate in the 
study.  
Investigational product, dosage and mode of administration: IPX203 (carbidopa -levodopa) 
Extended -Release capsules  for oral administration , provided in 4 dose strengths: 
• IPX203 35-140 mg CD -LD capsule  
• IPX203 52.5-210 mg CD -LD capsule  
• IPX203 70-280 mg CD -LD capsule  
• IPX203 87.5-350 mg CD- LD capsule  
Reference therapy, dosage and mode of administration: None 
Duration of treatment:  Nine (9) months of open- label therapy with IPX203 . 
Criteria for evaluation: 
• Safety: AEs, supine and standing orthostatic vital signs, and concomitant medications 
evaluated throughout the course of the stud y.  ECGs , clinical laboratory tests, physical 
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 7 of 112 examinations, and the C-SSRS will also be performed . 
• Clinical Utility Measures: PGI-S, CGI-S, TSA, PDSS-2, PDQ- 39, PAS, NMSS, GC SI, 
MDS -UPDRS Part  I to IV , ZBI -12, and E MSQ  will be assessed at every visit.  
Statistical methods:  For MDS -UPDRS, the total score (Parts I+II+III+IV), each of its 
components (Parts I through IV), and Parts II + Part III will be summarized across each of the 
time points in the trial (Baseline/Visit 1, Month 3, Month 6, and Month 9) to allow for assessmen t of the sustainability of the clinical effect of IPX203 over the 9 -month study 
duration.  Similarly, the PGI-S, CGI-S, TSA , PDSS-2, PDQ-39, PAS, NMSS, GCSI , ZBI-12, 
and E MSQ  will be summarized over time.  
The safety analysis will include all subjects who received at least one dose of study medication.  The incidence of treatment -emergent AEs and serious adverse events (SAEs) will 
be summarized.  Additionally, laboratory test data, physical examinations, vital signs, ECGs, and C- SSRS will be summarized acros s each time point in the trial.  
 
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 8 of 112 2. TABLE OF CONTENTS, LIST OF TABLES, AND LIST OF 
FIGURES  
TABLE OF CONTENTS  
SIGNATURE PAGE  .......................................................................................................................2  
INVESTIGATOR’S AGREEMENT  ...............................................................................................3  
STUDY CONTACT INFORMATION  ...........................................................................................4  
1. SYNOPSIS  ...................................................................................................................5  
2. TABLE OF CONTENTS, L IST OF TABLES, AND LIST OF FIGURES  .................8  
3. LIST OF ABBREVIATION S AND DEFINITIONS OF  TERMS .............................12  
4. INTRODUCTION  ......................................................................................................14  
5. TRIAL OBJECTIVES  ................................................................................................18  
6. INVESTIGATIONAL PLAN  .....................................................................................19  
6.1. Overall Study Design  ..................................................................................................19  
6.2. Number of Subjects  ....................................................................................................20  
6.3. Treatment Assignment  ................................................................................................20  
6.4. Dosing and Dose Determination Criteria  ...................................................................20  
6.5. Dose Adjustment Criteria  ...........................................................................................20  
6.6. Criteria for Study Termination  ...................................................................................20  
7. SELECTION AND WITHDRAWAL OF SUBJECTS  ..............................................21  
7.1. Subject Inclusion Criteria  ...........................................................................................21  
7.2. Subject Exclusion Criteria  ..........................................................................................21  
7.3. Subject Withdrawal Criteria  .......................................................................................21  
8. STUDY PROCEDURES  ............................................................................................23  
8.1. Visit 1 (Baseline)  ........................................................................................................27  
8.2. Visit 2 (Month 3)  ........................................................................................................27  
8.2.1.  Prior to Visit 2  ............................................................................................................27  
8.2.2.  At Visit 2 .....................................................................................................................27  
8.3. Visit 3 (Month 6)  ........................................................................................................28  
8.3.1.  Prior to Visit 3  ............................................................................................................28  
8.3.2.  At Visit 3 .....................................................................................................................28  
8.4. Visit 4 − Study Completion (Month 9) or Early Discontinuation ..............................29  
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 9 of 112 8.4.1.  Prior to Visit 4  ............................................................................................................29  
8.4.2.  At Visit 4 .....................................................................................................................29  
8.5. Early  Termination  .......................................................................................................30  
8.6. Blood Volume  .............................................................................................................30  
9. TREATMENT OF SUBJECTS  ..................................................................................31  
9.1. Description of Study Drug ..........................................................................................31  
9.2. Concomitant Medications  ...........................................................................................31  
9.2.1.  Permitted PD Medications and Surgical Treatments  ..................................................31  
9.2.2.  Prohibited PD Medications and Surgical Treatments  .................................................31  
9.3. Treatment Compliance  ................................................................................................32  
9.4. Randomization and Blinding ......................................................................................32  
10. STUDY DRUG MATERIALS  AND MANAGEMENT  ...........................................33  
10.1.  Study Drug  ..................................................................................................................33  
10.2.  Study Drug Packaging and Labeling  ..........................................................................33  
10.3.  Study Drug Storage  .....................................................................................................33  
10.4.  Study Drug Administration .........................................................................................34  
10.5.  Study Drug Dispensing and Accountability  ...............................................................34  
10.6.  Study Drug Handling and Disposal  ............................................................................34  
11. ASSESSMENT OF EFFICA CY ................................................................................35  
11.1.  Patient and Investigator Global Assessments  .............................................................35  
11.2.  Treatment Satisfaction Assessment (TSA)  .................................................................35  
11.3.  Parkinson’s Disease Sleep Scale- 2 (PDSS-2)  .............................................................35  
11.4.  Parkinson’s Disease Questionnaire-39 (PDQ-39)  ......................................................35  
11.5.  Parkinson Anxiety Scale (PAS)  ..................................................................................35  
11.6.  Non-Motor Symptom Assessment Scale for Parkinson’s Disease (NMSS)  ..............35  
11.7.  Movement Disorders Society Version of Unified Parkinson’s Disease Rating 
Scale (MDS -UPDRS)  .................................................................................................36  
11.8.  12-Item Zarit Burden Interview (ZBI -12) ..................................................................36  
11.9.  Early Morning Symptom Questionnaire (EMSQ)  ......................................................36  
12. ASSESSMENT OF SAFETY  .....................................................................................37  
12.1.  Safety Parameters  .......................................................................................................37  
12.2.  Adverse Events  ...........................................................................................................37  
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 10 of 112 12.2.1.  Definition of Adverse Event  .......................................................................................37  
12.2.2.  Recording Adverse Events  .........................................................................................37  
12.2.3.  Follow-up  ....................................................................................................................38  
12.2.4.  Relationship to Study Drug ........................................................................................38  
12.2.5.  Assessment of Severity  ...............................................................................................38  
12.3.  Serious Adverse Events  ..............................................................................................38  
12.3.1.  Definition of Serious Adverse Event  ..........................................................................38  
12.3.2.  Reporting Serious Adverse Events  .............................................................................39  
12.4.  Pregnancy  ...................................................................................................................39  
12.5.  Other Safety Parameters and Related Information  .....................................................40  
13. STATISTICS  ..............................................................................................................41  
13.1.  Study De sign and Sample Size Estimation  .................................................................41  
13.2.  Demographics and Baseline Characteristics  ...............................................................41  
13.3.  Analysis of Efficacy/Clinical Utility Data  ..................................................................41  
13.4.  Analysis of Dosing Data  .............................................................................................42  
13.5.  Population Analysis and Handling of Dropouts  .........................................................42  
13.6.  Analysis of Safety  .......................................................................................................42  
14. ADMINISTRATIVE PROCEDURES  .......................................................................43  
14.1.  Guidelines for Good Clinical Practice  ........................................................................43  
14.2.  Institutional Review Board Approval  .........................................................................43  
14.3.  Informed Consent  .......................................................................................................43  
14.4.  Study Monitoring ........................................................................................................43  
14.5.  Protocol Amendments  ................................................................................................43  
14.6.  Termination of Study  ..................................................................................................44  
14.7.  Case Report Forms  .....................................................................................................44  
14.8.  Investigator’s Final Conduct Report  ...........................................................................44  
14.9.  Records Retention  .......................................................................................................44  
15. PUBLICATION POLICY  ..........................................................................................45  
16. LIST OF REFERENCES  ............................................................................................46  
17. APPENDICES  ............................................................................................................48  
APPENDIX A.  RECOMMENDATIONS FOR IPX203 DOSING  ............................................49  
APPENDIX B.  COLUMBIA -SUICIDE SEVERITY RATING SCALE (C -SSRS)  ..................50  
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 11 of 112 APPENDIX C.  CLINICAL LABORATORY STUDIES  ...........................................................54  
APPENDIX D.  MOVEMENT DISORDERS SOCIETY VERSION OF THE UNIFIED 
PARKINSON’S DISEASE RATING SCALE (MDS -UPDRS)  ................................55  
APPENDIX E.  PATIENT GLOBAL IMPRE SSION OF SEVERITY (P GI-S) .........................89  
APPENDIX F.  CLINICAL GLOBAL IMPR ESSION OF SEVERITY ( CGI-S) .......................90  
APPENDIX G.  39-ITEM PARKINSON’S DISEASE QUESTIONNAIRE (PDQ-39)  .............91  
APPENDIX H.  GASTROPARESIS CARDINAL SYMPTOM INDEX (GC SI).......................97  
APPENDIX I. NON- MOTOR SYMPTOM ASSESS MENT SCALE FOR 
PARKINSON’S DISEASE (NMSS)  ..........................................................................98  
APPENDIX J.  PARKINSON’S DISEASE SLEEP SCALE -2 (PDSS-2)  ................................101  
APPENDIX K.  PARKINSON ANXIETY SC ALE (PAS)  .......................................................103  
APPENDIX L. TREATMENT SATISFACTI ON ASSESSMENT (TSA)  ..............................107  
APPENDIX M.  12-ITEM ZARIT BURDEN IN TERVIEW (ZBI -12) .....................................108  
APPENDIX N.  EARLY MORNING SYMPTOMS QUESTIONNAIRE (EMSQ)  .................109  
APPENDIX O.  COMPONENTS OF IPX203 ...........................................................................112  
 
 
LIST OF TABLES  
Table 1:  Abbreviations and Specialist Terms  ...........................................................................12  
Table 2:  Events Schedule for Study IPX203- B16-03 ...............................................................24  
Table 3:  Study Drugs for Study IPX203- B16-03 .....................................................................31  
 
 
LIST OF FIGURES  
Figure  1: IPX203- B16-03 Study Flow Chart  .............................................................................20  
 
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 12 of 112 3. LIST OF ABBREVIATION S AND DEFINITIONS OF TERMS 
The following abbreviations and specialist terms are used in this study protocol. 
Table 1: Abbreviations and Specialist Terms  
Abbreviation or Specialist Term  Explanation 
AADC  aromatic amino acid decarboxylase  
AE adverse event  
CD carbidopa  
CGI-S Clinical Global Impression  of Severity  
CR controlled release 
CRF  case report form  
COMT  catechol -O-methyltransferase  
C-SSRS  Columbia- Suicide Severity Rating Scale  
DBS  deep brain stimulator or  
deep brain stimulation 
ECG  electrocardiogram  
EMSQ  Early Morning Symptoms Questionnaire 
EOS  end of study  
ER extended release  
FDA Food and Drug Administration 
GCP  Good Clinical Practice  
GCSI  Gastroparesis Cardinal Symptom Index 
HIPAA  Health Insurance Portability and Accountability Act  
ICF informed consent form  
ICH International Conference on Harmonization 
IEC independent ethics committee  
IR immediate release  
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 13 of 112 Abbreviation or Specialist Term  Explanation 
IRB institutional review board  
IWRS  interactive web response system  
LD levodopa 
MAO monoamine oxidase inhibitors  
MAO-A MAO type A inhibitors  
MAO-B MAO type B inhibitors  
MDS -UPDRS  Movement Disorders Society version of the Unified Parkinson’s 
Disease Rating Scale  
M-EDL  Motor Aspects of Experiences of Daily Living  
m-MIDI  Modified -Minnesota Impulsive Disorders Interview  
nM-EDL  Non-Motor Aspects of Experiences of Daily Living  
NMSS  Non-Motor Symptom a ssessment scale for PD  
OLE  open- label extension  
PAS Parkinson Anxiety Scale 
PD Parkinson’s disease  
PDQ -39 39-item Parkinson’s Disease Questionnaire  
PDSS -2 Parkinson’s Disease Sleep Scale-2 
PGI-S Patient Global Impression  of Severit y 
PK pharmacokinetic (adjective)  
pharmacokinetics (singular noun)  
PI principal investigator  
SAE  serious adverse event  
TSA  Treatment Satisfaction Assessment  
US United States 
ZBI-12 12-Item Zarit Burden Interview  
 
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 14 of 112 4. INTRODUCTION 
Parkinson’s disease (PD) is a progressive neurodegenerative disorder of the extrapyramidal 
nervous system.  Levodopa (LD) used in combination with carbidopa (CD) is considered the 
gold standard for the symptomatic treatment of PD.  LD is a dopamine precursor converted to dopamine by aromatic amino acid decarboxylase (AADC).  Carbidopa is an AADC inhibitor that 
does not cross the blood-brain barrier.  When used in combination with LD, CD increases the 
plasma half -life of LD from 50 minutes to 1.5 hours.  Carbidopa inhibits the conversion of LD 
into dopamine in the periphery, thereby reducing the peripheral side- effects caused by dopamine 
and increasing the amount of LD available for transport into the brain.  The administration of CD with LD reduces the dose of LD required to produce a dopaminergic response by about 75 percent ( Sinemet prescribing information ). 
Due to its proven efficacy, LD is prescribed eventually to most subjects with PD.  However, long- term use of LD is associated with certain complications, including “wearing off” or “end-
of-dose effect,” where symptom control decreases and  the drug effects wear off sooner.  As the 
disease progresses further, motor complications, namely dyskinesias and motor “On/O ff” 
fluctuations, develop in about 50% of the patients after 5 years of treatment ( Fahn 1999 ).  Such 
motor complications can be a significant source of disability and their management is a major 
unmet need in the treatment of PD. 
Mechanisms underlying motor complications involving dyskinesias and “On/Off” fluctuations in 
PD are unclear.  The pulsatile nature of standard orally administered LD is thought to contribute 
to the appearance of motor complications.  Chronic intermittent pulsatile stimulation of the 
dopamine receptors that are under tonic control contributes to the development of dyskinesia in PD animal models as compared to animals treated with continuous infusion ( Juncos et al 1989, 
Engber et al 1989, Blanchet et al 1995).  In addition, unreliable absorption of LD potentially due 
to erratic gastric empting and variable in vivo dissolution of LD products is thought to contribute to the delay or inadequate response after oral dosing with standard CD-LD products ( Melamed 
1986, Kurlan et al 1988, Stocchi et al 1994).  These findings suggest that motor complications in 
patients with PD may be less likely to develop with continuous dopaminergic stimulation. 
Intraduodenal infusion of LD has been shown to significantly reduce motor complications and to 
reduce “Off” time.  The findings of infusion studies in PD patients indicate that the maintenance 
of stable plasma LD concentrations and the avoidance of low trough levels are effective in reducing “O ff” hours, increasing “ On” hours without disabling dyskinesia, and reducing the 
severity of dyskinesia versus standard oral LD formulations ( Mizuno 2007, Nilsson et al 2001, 
Nyholm et al 2005, Stocchi et al 2005).  These findings provide a strong rationale for t he 
development of an extended- release (ER) oral formulation that delivers a constant LD plasma 
concentration in order to optimize relief of PD symptoms, and to minimize “O ff” time and 
dyskinesia.  
IPX203 is an investigational product containing CD- LD that is being developed by Impax 
Laboratories, LLC  (Impax).  The primary objective of the IPX203 program is to develop an 
extended release product that can attain therapeutic LD plasma concentrations rapidly and maintain constant LD plasma concentrations for a longer duration than currently approved 
products with minimal peak -to-trough fluctuations.  IPX203 is designed to be dosed 
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 15 of 112 approximately every 7 to 8 hours, based on the plasma LD concentration time profile observed in 
subjects with advanced PD (Study IPX203- B14-02 and IPX203- B16-01).  
Study IPX203- B14-02 characterized the PK and pharmacodynamics of IPX203 following a 
single dose in subjects with advanced PD versus immediate -release ( IR) CD -LD and Rytary®.  
Twenty -six (26) subjects were randomized with 25 subjects completing all 3 treatments.  One 
subject discontinued study early due to subject withdrawal.  Administration of IPX203 yielded 
an initial increase in LD plasma concentrations that was similar to  both IR CD-LD and Rytary 
but maintained LD concentrations longer.  IPX203 provided a longer pharmacodynamic duration 
of effect compared with IR  CD-LD and Rytary, including “Off” time and “Good on” t ime based 
on the Assessment of Subject’s Motor State and on several of the MDS -UPDRS Part III 
improvement thresholds.  Of the 26 subjects who received at least one of the 3 treatments, 9 subjects (34.6%) reported at least one treatment- emergent adverse event (AE).  None of these 
subjects reported a SAE nor did any subjects prematurely discontinue the study because of an AE.  Adverse events were reported by more subjects during IR CD-LD (28.0%) and IPX203 
(19.2%) than during Rytary (8.0%) treatment.  None of the r eported AEs were classified as 
severe.  Adverse events reported by 2 or more subjects included dizziness (3 subjects), nausea 
(2 subjects), and hypertension (2 subjects).  The numbers of subjects reporting these AEs during 
any single treatment period were small (0 to 2  subjects).  Two subjects reported dizziness during 
IR CD-LD treatment and one subject each during IPX203 and Rytary treatments.  Hypertension 
was reported by a total of 2  subjects, both reporting this AE during IPX203 and IR CD-LD 
treatments and 1 subject during Rytary treatment.  Two subjects reported nausea only during the 
IR CD-LD treatment period.  Of the 9  subjects reporting AEs, 6 (23.1%) subjects reported AEs 
that were assessed as related to treatment, including all of the reports of dizziness, nausea, and 
dyskinesia (1 subject).  Most subjects reported AEs that were assessed as mild  in severity, but 
during treatment with IPX203, 2 subjects (7.7%) reported moderate AEs (dyskinesia and hypertension), during IR CD-LD treatment 1  subject (4.0%) reported atrial flutter of moderate 
severity, and during Rytary treatment, 1 subject (4.0%) reported dyskinesia of moderate severity.  
The pharmacokinetics and pharmacodynamics of IPX203 were studied in a randomized, open-
label, rater -blinded, multicenter, 2- treatment, 2 -period, multiple-dose crossover study (IPX203-
B16-01).  Twenty -eight (N=28) advanced PD subjects were randomized to 1 of 2  dosing 
sequences , with each treatment period lasting 15 days and separated by a 1- week wash -out 
period where subjects return to their usual stable pre- study CD -LD r egimen .  The objectives of 
this study are to compare the PK, pharmacodynamics, efficacy, and safety of IPX203 with IR CD-LD after single and multiple dosing.  Subjects were permitted to take allowed non- CD-
LD-based PD medications throughout the study if dosing regimens had been stable for at least 
4 weeks .  Subjects were instructed to take their last dose of CD-LD no later than 10:00 PM on 
the evening prior to Day 1 of each treatment period and to 
withhold dosing for at least 5 hours 
before arriving at the site on Day 15 of each treatment period .  On Day  1 of the IR CD -LD 
treatment period, subjects were started with a single dose of their usual prestudy first morning 
IR CD-LD dose.  On Day 1 of the IPX203 treatment period, subjects were  started  with a single  
dose of IPX203 based on their usual prestudy first morning IR CD -LD dose using a LD 
conversion of 100 mg IR LD to 360 mg of IPX203 LD.  During the IR CD -LD treatment period, 
the initial dosing regimen of IR  CD-LD was the same as the subject’s stable prest udy regimen.  
During the IPX203 treatment period, the IPX203 regimen for subsequent doses for the day was 
determined by identifying  the most frequent prestudy IR LD dose in milligrams that the subject 
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 16 of 112 received in the afternoon and evening and administering IPX203 using a LD conversion of 
100 mg IR LD to 270 mg of IPX203 LD.  The protocol recommended that IPX203 be dosed 
approximately every 7 to 8 hours.  During Days 1 through 9 of both treatment periods, 
investigators had the opportunity to adjust each subject’s study medication regimen if necessary 
to optimize efficacy and safety.   Pharmacokinetics and pharmacodynamics (MDS- UPDRS Part 
III and Assessments of Subject’s Motor State) were periodically evaluated on Day 1 and Day 15 of 
each treat ment period by qualified clinical staff who were blinded to dosing.  
Data from this multiple -dose study confirmed the PK and pharmacodynamic results observed in 
the single dose study with IPX203: 
• PK data from 27 subjects indicates IPX203 shows a rapid incre ase in LD 
concentrations followed by extended- release characteristics.  Following IPX203; 
initial increases in LD concentrations were comparable to that from IR  CD-LD.  
Bioavailability of LD following IPX203 was ~89 % relative to IR  CD-LD.  LD 
plasma concentrations were sustained longer after IPX203 treatment than after 
IR CD-LD and support dosing every 8 hours.  No accumulation of LD was evident at 
steady -state following IPX203 or IR CD -LD.  Plasma LD concentrations following 
IPX203 were characterized by lower peak -to-trough fluctuation.  No time -variant or 
time-dependent changes were noted in PK of CD or LD following IPX203. 
• IPX203 demonstrated an onset of effect that was comparable to IR CD -LD in 
MDS -UPDRS Part III scores.  IPX203 prolonged the duration over which 
MDS -UPDRS Part III scores were improved by prespecified threshold changes from 
baseline (≥4, ≥7, and ≥13 units). 
• IPX203 provides a significant decrease in “Off” time and a significant increase in “Good on” time compared to IR CD -LD treatment on Da y 1 and Day 15 when 
assessed by the Investigator’s Assessment of Subject’s Motor State.  Subjects treated with IPX203 did not experience a significant increase in “On” time with troublesome dyskinesia compared to IR CD -LD. 
• Subjects achieved significant imp rovements in “Off” time, “Good on” time, and 
frequency of motor state fluctuations based on the 3 -day PD Diar ies. 
• Twenty -eight subjects were enrolled in the multiple -dose study and 27 subjects 
completed both treatments.  Safety results were as follows:  
− One subject discontinued during the IPX203 treatment period due to an AE 
(orthostatic hypertension) that was considered possibly related to treatment. 
− A total of 39.3% (11/28) of treated subjects reported at least one treatment 
emergent AE, including 35.7% (10/28) during IPX203 treatment and 7.4% (2/27) 
during IR CD- LD treatment.  Eight subjects reported AEs that were related to 
treatment (8 subjects during IPX203 treatment and 1 during IR CD- LD 
treatment).  
− Two subjects experienced serious adverse events (SAEs ).  One subject reported 
increased hypertension of m ild severity during IPX203 treatment that was 
considered unrelated to treatment and resolved.  A second subject reported 
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 17 of 112 moderate to severe dehydration, diarrhea, and atrial fibrillation during the 
washout period that were considered unrelated to treatment  and resolved. 
− AEs reported in 2 or more subjects included nausea (2), dizziness (2), and 
dyskinesia (5), all of mild or moderate severity, and all during the IPX203 
treatment.  
Study IPX203- B16-02 is a randomized, double-blind, double-dummy, active-control, parallel-
group, multicenter study designed to compare the efficacy, safety and tolerability of IPX203 with IR CD-LD in CD -LD-experienced subject s with advanced PD and motor fluctuations following 
13 weeks of therapy.  
Subject s who successfully complete Study IPX203- B16-02 may have the opportunity to enroll in 
this 9 -month, open- label safety extension study.  
 
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 18 of 112 5. TRIAL OBJECTIVES 
The objective of this study is to evaluate the long- term safety and clinical u tility of IPX203 in 
subjects  with advanced Parkinson’s disease (PD) who have motor fluctuations . 
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 19 of 112 6. INVESTIGATIONAL P LAN 
6.1. Overall Study Design  
Subjects who have successfully completed Study IPX203- B16-02 (A Randomized Controlled 
Study to Compare the Safety and Efficacy of IPX203 with  Immediate -Release Carbidopa -
Levodopa in Parkinson’s Disease Patients with Motor Fluctuations) may be offered the 
opportunity to enroll in this 9-month, multicenter open- label study ( Figure  1).  The study consists 
of a baseline visit (Visit 1) followed by 3 visits (V isits 2 to 4) spaced at approximately 3-month 
intervals.  For subjects who successfully complete Study IPX203- B16-02, the baseline visit 
(Visit 1) of this study will occur coincident with the End of Study (EOS) Visit 7 of the preceding 
study.   After provid ing written informed consent (and signing Health Insurance Portability and 
Accountability Act  [HIPAA ] authorization for subjects at United States [US]  sites only), 
confirmation of eligibility and baseline procedures will be performed.  Subjects will be initially started  on the final IPX203 dosing regimen that was determined during the IPX203 dose 
conversion period of Study IPX203- B16-02.  Investigators are permitted to adjust the dosing 
regimen of IPX203 during this  study to achieve the optimal balanc e of efficacy and safety and 
any changes will be recorded.  
Subjects may continue to take their non- LD-containing PD medications (including dopamine 
agonists, amantadine, and selective monoamine oxidase- B (MAO -B) inhibitors [ safinamide, 
rasagiline and seleg iline]) during the study .  Changes in doses or in dosing regimens of all non-
CD-LD PD medications and/or the addition of new non- CD-LD PD medications will be 
captured.   Supplemental CD  and benserazide, apomorphine, and the addition of catechol-O-
methyltran sferase (COMT) inhibitors (eg, entacapone, opicapone, and tolcapone) can be initiated 
during the study. 
Adverse events, supine and standing orthostatic vital signs, and concomitant medications will be 
evaluated throughout the course of the study.  Electrocardiograms (ECGs), clinical laboratory 
tests, physical examinations, and the Columbia- Suicide Severity Rating Scale (C -SSRS) will also 
be performed.  The following clinical utility measures will be assessed:  Patient Global 
Impression of Severity (PGI -S), Clinician Global Impression of Severity (CGI -S), Treatment 
Satisfaction Assessment (TSA), Parkinson’s Disease Sleep Scale -2 (PDSS-2), the 39- item 
Parkinson’s D isease Questionnaire (PDQ-39), Parkinson Anxiety Scale (PAS), Non-Motor 
Symptom assessment scale (NMSS) for Parkinson’s disease, Gastroparesis Cardinal Symptom 
Index (GCSI), The Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS -UPDRS) Part s I to IV , 12-Item Zarit Burden Interview (ZBI -12), and Early Morning 
Symptoms Questionnaire ( EMSQ) .  Visit 4 is the end of study (EOS). 
 
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 20 of 112 Figure 1: IPX203-B16-03 Study Flow Chart 
 
 
 
  
 
 
6.2. Number of Subjects  
Subjects who successfully complete IPX203- B16-02 are elig ible to enroll in this open- label 
extension ( OLE ) study ; it is estimated that approximately 300 subject s will enroll.  
6.3. Treatment Assignment  
All subjects will receive IPX203. 
6.4. Dosing and Dose Determination Criteria  
Subjects will start on the IPX203 dosing regimen that was determined at the end of the IPX203 
dose conversion period of Study IPX203- B16-02 (Visit 4 of Study IPX203- B16-02). 
6.5. Dose Adjustment Criteria 
Investigators are permitted to adjust the dosing regimen of IPX203 during the study to achieve 
the optimal balance of efficacy and safety ; all dosing changes will be recorded.  
Recommendations for dosing IPX203 are  provided in Appendix A . 
6.6. Criteria for Study Termination  
The Sponsor has the right to terminate this study and remove all study material from the study site at any time for medical or administrative reasons.  The Sponsor will endeavor to give 
adequate notice to allow safe withdrawal of subjects from the study. 
Baseline  
Visit 1 
Month 9  
Visit 4  
End of Study  
Month 3 
Visit 2  
IPX203- B16- 02 
Completers  
Month 6 
Visit 3  ~    
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 21 of 112 7. SELECTION AND WITHDR AWAL OF SUBJECTS 
Subject s must meet all of the following inclusion criteria to qualify for enrollment.   Subjects who 
have any of the following exclusion criteria will not be enrolled in the study.  
7.1. Subject Inclusion Criteria  
1. Successfully completed Study IPX203- B16-02. 
2. Able  to provide written informed consent prior to the conduct of any study- specific 
procedures. 
3. Female subjects of childbearing potential must have a negative urine pregnancy test at the 
baseline visit (Visit 1).  
4. Agrees to use a medically acceptable method of contraception throughout the study and 
for 6 weeks after completing the study.  Medically acceptable methods of contraception that may be used by the subject and/or partner include but are not limited to:  abstinence, 
oral contraception, NuvaRing or transd ermal systems, diaphragm with vaginal 
spermicide, intrauterine device, condom and partner using vaginal spermicide, surgical 
sterilization (6  months), progestin implant or injection, or postmenopausal female (no 
menstrual period for ˃2 years) or vasectomy (˃6 months). 
7.2. Subject Exclusion Criteria 
1. Intends to use any doses of Rytary or Duopa™ during this study. 
2. Plans to use an investigational treatment other than IPX203 during the course of this study. 
3. Neurosurgical ablation treatment for PD is planned or anticipated during the study period.  Implantation of a deep brain stimulator (DBS) for the treatment of PD is permitted during this study.  
4. Subjects who, in the opinion of the clinical investigator, should not participate in the study.  
7.3. Subject Withdrawal C riteria 
Site personnel should make every effort to conduct all protocol- specific procedures to complete 
the study.  A subject may be discontinued from the study due to the following reasons: 
1. Withdrawal by subject 
2. Adverse event  
3. Lack of efficacy  
4. Study termin ated by Sponsor 
5. Protocol deviation 
6. Noncompliance with study drug 
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 22 of 112 7. Lost to follow-up 
8. Death  
9. Other  
Subjects who withdraw early from the study will not be replaced.  The reason or reasons for 
discontinuation wil l be specified and documented . 
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 23 of 112 8. STUDY P ROCEDURES  
The procedures to be performed at each study visit are summarized in Table 2. 
 
Protocol No. IPX203 -B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 24 of 112 Table 2: Events Sc hedule for Study IPX203 -B16-03 
 Visit 1 
Baseline 9 Months of  
IPX203 Therapy 
Study Drug 
Resupply 
Months 1 -2 Visit 2 Study Drug 
Resupply 
M
onths 4-5 Visit 3 Study Drug 
Resupply 
M
onths 7-8 Visit 4/ 
Early 
Term
ination 
Study Month  0  3  6  9 
ICF and HIPAA Authorization  X       
Check Inclusion/Exclusion Criteria  X       
Update Medical History  X       
Physical Examination  X      X 
Vital Signs  X  X  X  X 
Weight  X  X  X  X 
C-SSRS  X  X  X  X 
Clinical Laboratory Tests X  X  X  X 
Urine Pregnancy Test  X       
ECG X  X  X  X 
MDS -UPDRS Parts I -IV X  X  X  X 
PGI-S X  X  X  X 
CGI-S X  X  X  X 
PDQ- 39 X  X  X  X 
GCSI  X      X 
NMSS X  X  X  X 
PDSS-2 X  X  X  X 
PAS  X  X  X  X 
TSA    X  X  X 
Protocol No. IPX203 -B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 25 of 112  Visit 1 
Baseline 9 Months of  
IPX203 Therapy 
Study Drug 
Resupply 
Months 1 -2 Visit 2 Study Drug 
Resupply 
M
onths 4-5 Visit 3 Study Drug 
Resupply 
M
onths 7-8 Visit 4/ 
Early 
Term
ination 
Study Month  0  3  6  9 
ZBI-12 X  X  X  X 
EMSQ  X  X  X  X 
Contact phone calls    X  X  X 
Contact IWRS to d ispense study medication X X X X X X  
Collect empty medication bottles and any unused 
study drug/Perform study drug accountability  X X X X X X 
Adverse Events  X  X  X  X 
Concomitant Medications  X  X  X  X 
a Visit 1 is expected to occur on the same day as the End -of-Study Visit (Visit 7) of Study IPX203- B16- 02 but not later than 1 week.  After the subject provides 
consent for this study, carry over and record information from procedures at the End -of-Study Visit of IPX203- B16- 02 as t he Baseline data for this study . 
b Subjects enrolled at sites in the United States (US) must sign HIPAA authorization prior to the conduct of any study -specific procedures. 
c Record vital  signs (blood pressure, heart rate, respiratory rate, and temperature [Visit 1 and Study Exit only]) after subject has been resting supine for at least 
5 minutes, then record orthostatic blood pressure and heart rate after subject has been standing for approximately 2 minutes.  
d See Appendix  B. 
e See Appendix  C. 
f This test will be performed at Visit 1 of this study.  
g See Appendix  D. 
h See Appendix  E. 
i See Appendix  F. 
j See Appendix  G. 
k See Appendix  H. 
l See Appendix  I. 
m See Appendix  J. 
n See Appendix  K. 
o See Appendix  L. 
p See Appendix  M. 
q See Appendix  N. 
Protocol No. IPX203 -B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 26 of 112 r Contact phone calls for Visits 2 through 4:  
•  Following Visit 1, contact subjects weekly for the first month and then approximately monthly thereafter between visits to review the subject’s medication 
dosing regimen.  
•  Instruct subjects to call the study site be fore making any changes to their IPX203 dosing regimen.  
•  Update and record concomitant medications and IPX203 dose adjustments.  
•  Contact subjects 1 day prior to Visits 2 to 4 to remind them to bring back any unused medication and empty medication bott les. 
CGI-S = Clinical Global Impression of Severity Scale; C -SSRS =  Columbia -Suicide Severity Rating Scale; ECG = electrocardiogram; EMSQ = Early Morning 
Symptoms Questionnaire; GCSI = Gastroparesis Cardinal Symptom Index; HIPAA = Health Insurance Portability and Accountability Act; ICF = informed 
consent form; IWRS = interactive web response system; PAS = Parkinson Anxiety Scale; PD = Parkinson’s disease; PDQ -39 = 39- Item Parkinson’s Disease 
Questionnaire; PDSS -2 = Parkinson’s Disease Sleep Scale -2; PGI -S = Patient Global Impression of Severity Scale; MDS -UPDRS = MDS version of Unified 
Parkinson’s Disease Rating Scale; NMSS = Non -Motor Symptom assessment scale for PD ; TSA = Treatment Satisfaction Assessment ; ZBI -12 = 12- Item Zarit 
Burden Interview . 
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 27 of 112 8.1. Visit 1 (Baseline)  
Visit 1 is expected to occur on the same day as the End-of- Study Visit (Visit 7) of Study 
IPX203- B16-02.  After the subject provides consent for this study, carry over and record 
information from procedures at the End- of-Study Visit of IPX203- B16-02 as the baseline data 
for this study. 
After the subject has signed the informed consent (and HIPAA authorization for subjects at US 
sites) , complete the following procedures and assessments: 
• Review and record study entry criteria ( Section  7). 
• Update the subject’s medical history . 
• Perform urine pregnancy test for females of childbearing potential.  
• Complete the 12-Item Zarit Burden Interview (ZBI -12) ( Appendix M ). 
• Administer the E arly Morning Symptoms Questionnaire (EMSQ) (Appendix N ). 
• Contact the interactive web response system ( IWRS ) to dispense study drug. 
• Instruct the subject  on dosing. 
• After Visit 1, contact subjects weekly for the first month and then approximately 
monthly thereafter to discuss the subject’s dosing regimen.  Record the subject’s 
current IPX203 dose regimen . 
• Instruct subjects to call the study site before making any changes to their IPX203 dosing regimen. 
• Subjects may return for study drug resupply approximately every 1 to 2 months as needed.  
8.2. Visit 2 (Month 3)  
8.2.1. Prior to Visit 2  
Call the subjects prior to Visit 2 and remind them to bring any unused study medication and 
empty medication bottles to Visit 2. 
8.2.2. At Visit 2  
• Collect unused study drug and empty bottles. 
• Review study dr ug accountability . 
• Update IPX203 regimen (dose, frequency, number of capsules ) and concomitant 
medications . 
• Assess vital signs after subject is supine for at least 5 minutes (blood pressure, heart 
rate, temperature and respiratory rate) and then assess ort hostatic blood pressure and 
heart rate after subject is standing for approximately 2  minutes.  
• Record AEs.  
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 28 of 112 • Weigh the subject.  
• Perform a 12 -lead ECG.  
• Administer C -SSRS ( Appendix B ) 
• Collect blood and urine samples for clinical laboratory studies ( Appendix C ). 
• Administer MDS -UPDRS Parts I through IV ( Appendix D ). 
• Determine PGI -S and CGI- S scores ( Appendix E  and Appendix F , respectively ). 
• Complete PDQ -39 ( Appendix G ). 
• Perform NMSS (Appendix I ). 
• Complete the PDSS -2 (Appendix J ). 
• Complete PAS (Appendix K ). 
• Complete TSA (Appendix L ). 
• Complete the ZBI-12 (Appendix M ). 
• Administer the EMSQ  (Appendix N ). 
• Contact IWRS and enter study drug dispensing information. 
• Dispense study drug and provide dosing instructions. 
• Subjects may return for study drug resupply approx imately every 1 to 2 months as 
needed.  
• Instruct subjects to call the study site before making any changes to their IPX203 
dosing regimen. 
• Call subjects approximately monthly to discuss IPX203 dosing .  Record the subject’s 
current IPX203 dose regimen . 
8.3. Visit 3 (Month 6)  
8.3.1. Prior to Visit 3  
Call the subjects prior to Visit 3 and remind them to bring any unused study medication and empty medication bottles to Visit 3 . 
8.3.2. At Visit 3  
• Collect unused study drug and empty bottles. 
• Review study drug accountability . 
• Update IPX203 regimen (dose, frequency, number of capsules ) and other concomitant 
medications . 
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 29 of 112 • Assess vital signs after subject is supine for at least 5 minutes (blood pressure, heart 
rate, temperature and respiratory rate) and then assess orthostatic blood pressure and 
heart rate after subject is standing for approximately 2 minutes.  
• Record AEs.  
• Weigh the subject.  
• Perform a 12 -lead ECG.  
• Administer C -SSRS ( Appendix B ). 
• Collect blood and urine samples for clinical laboratory studies ( Appendix C ). 
• Adm inister MDS -UPDRS Parts I through IV ( Appendix D ). 
• Determine PGI -S and CGI- S scores ( Appendix E  and Appendix F , respectively)  
• Complete PDQ -39 ( Appendix G ). 
• Perform NMSS (Appendix I ). 
• Complete the PDSS -2 (Appendix J ). 
• Complete PAS ( Appendix K ). 
• Complete TSA ( Appendix L ). 
• Complete the ZBI-12 ( Appendix M ). 
• Administer the EMSQ ( Appendix N ). 
• Contact IWRS and enter study drug dispensing information. 
• Dispense study drug and provide dosing instructions. 
• Subjects may return for study drug resupply approximately every 1 to 2 months as needed . 
• Instruct subjects to call the study site before making any changes to their IPX203 
dosing regimen. 
• Call subjects approximately monthly to discuss IPX203 dosing.  R ecord the subject’s 
current IPX203 dose regimen . 
8.4. Visit 4 − Study Completion (Month 9)  or Early Discontinuation  
8.4.1. Prior to Visit 4  
Call the subjects prior to Visit 4 and remind them to bring any unused study medication and 
empty medication bottles to the visit.  
8.4.2. At Visit 4  
• Collect unused study drug and empty bottles. 
• Review study drug accountability . 
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 30 of 112 • Update IPX203 regimen ( dose, frequency, number of capsules ) and other concomitant 
medications.  
• Asse ss vital signs after subject is supine for at least 5 minutes (blood pressure, heart 
rate, temperature and respiratory rate) and then assess orthostatic blood pressure and 
heart rate after subject is standing for approximately 2 minutes.  
• Record AEs.  
• Weigh the subject.  
• Perform physical exam including weight. 
• Perform a 12 -lead ECG.  
• Administer C -SSRS (Appendix B ). 
• Collect blood and urine samples for clini cal laboratory studies ( Appendix C ). 
• Administer MDS -UPDRS Parts I through IV ( Appendix D ). 
• Determine PGI -S and CGI- S scores ( Appendix E  and Appendix F , respectively).  
• Complete PDQ -39 ( Appendix G ). 
• Complete GCSI ( Appendix H ). 
• Perform NMSS (Appendix I ). 
• Complete the PDSS -2 (Appendix J ). 
• Complete PAS ( Appendix K ). 
• Complete the TSA ( Appendix L ). 
• Complete the ZBI-12 ( Appendix M ). 
• Administer the EMSQ ( Appendix N ). 
• Contact IWRS to report subject  disposition. 
8.5. Early Termination  
Subjects who withdraw early should complete Study Exit procedures described in Section  8.4. 
8.6. Blood Volume  
Safety blood draws:  Approximately 20 mL of blood will be drawn at each study visit for a 
combined total of 80 mL. 
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 31 of 112 9. TREATMENT OF SUBJECTS 
9.1. Description of Study Drug  
Study drugs wi ll be provided by Impax for this study: 
IPX203 (carbidopa-levodopa) Extended-Release Capsules, in four strengths, containing 
35-140 mg, 52.5-210 mg, 70-280 mg, and 87.5-350 mg of CD -LD, for oral administration.  
Table 3: Study Drugs for Study IPX203 -B16-03 
Investigational Product  Dosage Form and Strength 
(mg CD-LD) Manufacturer  
IPX203 (carbidopa-levodopa) 
Extended- Release Capsules  35-140 mg capsule 
52.5-210 mg capsule 70-280 mg capsule  
87.5-350 mg capsule Impax  Laboratories, LLC  
9.2. Concomitant Medications  
9.2.1. Permitted PD Medications and Surgical Treatments  
Concomitant therapy with amantadine, selective monoamine oxidase (MAO) type B inhibitors 
(eg, safinamide, selegiline, rasagiline), anticholinergic PD medications (eg, benztropine, 
trihexyphenidyl), hypnotics (including low doses of quetiapine ≤ 25 mg per day), dopamine 
agonists, including apomorphine, supplemental CD, and COMT inhibitors are allowed provided the doses and regimens (and any adjustments) are recorded on the concomitant medication form.  
Implantation of a deep brain stimulator (DBS) for the treatment of PD is permitted during this study provided the stimulation settings are recorded. 
Although apomorphine, supplemental CD, COMT inhibitors, and DBS were not permitted in 
Study IPX203- B16-02, these treatments may be initiated during the current study. 
All concomitant medications taken during this study will be recorded.  
9.2.2. Prohibited PD Medications and Surgical Treatments  
Prohibited treatments during the study include the following: 
• Any doses of Rytary and Duopa during this study. 
• Nonselective MAO inhibitors or selective MAO type A inhibitors (MAO -A). 
• Neurosurgical ablation treatment procedures for PD. 
• Investigational agents other than IPX203. 
• Dopamine antagonists with the exception of low doses (≤  25 mg) of quetiapine for 
sleep.  
A subject who reports the use of any prohibited medications will be discontinued. 
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 32 of 112 9.3. Treatment Compliance  
Study drug accountability and reconciliation will be performed by the site staff and the study 
monitor. 
9.4. Randomization and Blinding  
This is a nonrandomized open- label study.  
 
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 33 of 112 10. STUDY DRUG MATERIALS  AND MANAGEMENT  
10.1. Study Drug  
The study drug is IPX203  (carbidopa-levodopa) Extended- Release capsules for oral 
administration,  provided in 4 dose strengths: 
• IPX203 35-140 mg CD- LD capsule  
• IPX203 52.5-210 mg CD- LD capsule  
• IPX203 70-280 mg CD- LD capsule  
• IPX203 87.5-350 mg CD- LD capsule.  
IPX203 will be supplied by Impax. 
10.2. Study Drug Packaging and Labeling  
Impax or designee will provide study medications in bottles with appropriate labeling affixed. 
Labels on the study medication may include the following information: 
• Name, address, and phone number of the Sponsor. 
• Pharmaceutical dosage form/route of administration, quantity of dosage units, the 
name/identifier, and  strength/potency. 
• Batch and/or code number to identify the contents and packaging operation. 
• Trial reference code ( protocol number). 
• Trial subject identification number and where relevant, the visit number. 
• Name of Investigator. 
• Directions for use: Take capsule(s) orally with water as directed.  
• For clinical trial use only . 
• Storage information:  Store at room temperature between 15-30°C (59-86°F). 
• Protect from light and moisture.  
• Period of use (use- by date, expiry date or retest date as applicable), in mon th/year 
format and in a manner that avoids any ambiguity. 
• Keep out of reach of children. 
• Caution statement:  Caution: New Drug —Limited by Federal (or United States) law 
to investigational use.  
10.3. Study Drug Storage  
The study medications should be stored at 25°C (77°F), with excursions permitted to 15°C to 
30°C (59°F to 86°F).  They should be stored in a tightly closed container, protected from light 
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 34 of 112 and moisture.  Storage temperature excursions below 15°C (59°F)  or above 30°C (86°F) should 
be reported to Product Development at Impax or its designee. 
10.4. Study Drug Administration  
Subjects will be instructed to take their medications with approximately 240 mL of room-
temperature water.  The capsules should not be crushed or chewed.  
10.5. Study Drug Dispensing and Accountability  
The Investigator must ensure that all study medication received at the study site is inventoried and accounted for, and that dispensed study medication is recorded in the subject’s source documents, the CRF, and the study medication inventory log.  Site personnel must not relabel or 
reassign study medication to other subjects or to individuals not enrolled in the study.  The study 
monitor verifies medication accountability during monitoring visits.  
10.6. Study Dru g Handling and Disposal  
The Investigator must retain and properly store all partially used and unused study medication until authorized by Impax regarding disposition. 
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 35 of 112 11. ASSESSMENT OF EFFICACY  
To allow for assessment of the sustainability of the clinical eff ect of IPX203 over the 9-month 
study duration, the following clinical utility measures will be assessed at every visit: PGI -S, 
CGI-S, TSA, PDSS-2, PDQ-39, PAS, NMSS, MDS- UPDRS Parts I to IV , ZBI -12 and EMSQ. 
11.1. Patient and Investigator Global Assessments  
• Patient Global Impression of Severity (PGI -S) (Appendix E ):  The subject  will 
determine the severity of the disease on a 7 -point scale ranging from “Norm al, not at 
all ill” (1) to “Extremely severely ill” (7) at the time of the assessment.  
• Clinical Global Impression of Severity  (CGI -S) (Appendix F ):  The clinician will 
determine the severity of the disease on a 7 -point scale ranging from “Normal, not at 
all ill” (1) to “Among the most extremely ill of subjects” (7) at the time of the 
assessment.  
11.2. Treatment Satisfaction Assessment (TSA ) 
The TSA  is a single -question, self-reported questionnaire ( Appendix L ).  The subject  will 
determine his/her treatment satisfaction using a 7-point scale ranging from “ Very much 
dissatisfied ” (1) to “ Very much satisfied” (7) at the time of the assessment.  
11.3. Parkinson’s Disease Sleep Scale -2 (PDSS -2) 
The PDSS-2 is 15- item self -reported questionnaire ( Appendix J ).  Three domains are defined:  
disturbed sleep (Questions 1-3, 8, 14), motor symptoms at night (Questions 4-6, 12, 13), PD symptoms at night (Questions 7, 9-11, 15). 
11.4. Parkinson’s Disease Questionnaire -39 (PDQ-39) 
The PDQ -39 is a self -reported questionnaire ( Appendix G ).  Using the 39 items, 8 domains are 
defined:  mobility (Questions 1 -10), activities of daily living (ADL)  (Questions 11-16), 
emotional well-being (Questions 17-22), stigma (Questions 23-26), social support (Questions 27-29), cognition (Questions 30-33), communication (Questions 34-36) and bodily discomfort (Questions 37-39). 
11.5. Parkinson Anxiety Scale (PAS)  
The PAS is a 12 -item subject - or observer-rated questionnaire with 3 domains:  persistent anxiety 
(Questions A.1- A.5), episodic anxiety (Questions B.1-B.4) and avoidance anxiety (Questions 
C.1-C.3) ( Appendix K ). 
11.6. Non-Motor Symptom Assessment Scale for Parkinson’s Disease 
(NMSS) 
The NMSS  is a 30 -item, investigator -rated questionnaire ( Appendix I ).  The NMSS contains 
9 domains: cardiovascular (Questions 1, 2), sleep/fatigue (Questions 3-6), mood/cognition 
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 36 of 112 (Questions 7-12), perceptual problems (Questions 13-15), attention/memory (Questions 16-18), 
gastrointestinal (Questions 19 -21), urinary (Questions 22-24), sexual function (Questions 25, 
26), and miscellaneous (Questions 27-30). 
11.7. Movement Disorders Society Version of Unified Parkinson’s Disease 
Rating Scale  (MDS-UPDRS)  
The MDS -UPDRS ha s 4 parts ( Appendix D ): 
• Part I:  Non -Motor Aspects of Experiences of Daily Living (nM- EDL) has 
2 components.  Component IA contains a number of behaviors assessed by the 
investigator with all pertinent information from the subjects and caregivers.  
Component IB is completed by the subject with or without help from the caregiver 
but independent of the investigator.  These sections can be reviewed by the rater to 
ensure all questions are answered clearly and the rater can help explain any ambiguities.  
• Part II:  Motor Aspects of Experiences of Daily Living (M -EDL) is a self -
administered questionnaire but can be reviewed by the investigator to ensure 
comple teness and clarity.  
• Part III:  Motor Examination assesses the motor signs of PD and has instructions for the rater to give to  or to demonstrate to the subjec t.  It is completed by the rater.  
• Part IV:  Motor  Complications integrates subjec t-derived information with the rater’s 
clinical observations and judgements and is completed by the rater.  It contains 
instructions for the rater and instructions to be read to the subjec t. 
11.8. 12-Item Zarit Burden Interview (ZBI -12) 
The Zarit Burden Intervie w (ZBI) is used to assess the perceived burden of family caregivers 
who provide assistance to patients with long-term progressive neurological disorders, including PD.  The ZBI -22 consists of 22 items with five ordered frequency- related response categories  
scored 0 (never) to 4 (nearly always), except for the final item, which has 5 ordered intensity-
related response categories (0 = not at all; 4 = extremely).  All 22 items are used to calculate a 
total score that can range between 0 and 88 (88 = more burden).  A total score of 21 has been suggested as a burden cut point.  The ZBI-12 is a 12- item short form of the ZBI -22 and has been 
shown to be reliable and valid and to produce results that are similar to the longer version (Hagell et al 2017 , Bédard et al 2001 ) (Appendix M ) while minimizing respondent time and 
burden.  The ZBI-12 should be c ompleted by the same caregiver during each visit.  
11.9. Early Morning Symptom Questionnaire (EMSQ)  
The EMSQ is a 3 -question, subject- rated questionnaire (Appendix N ) that is used to assess 
whether a subject is experiencing any of 10 early morning PD symptoms by answering questions about prevalence (Question 1), severity (Question 2), and response to the first morning dose of 
PD medications (Question 3).  Study site staff will complete this questionnaire by questioning 
subjects during each study visit. 
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 37 of 112 12. ASSESSMENT OF SAFETY 
12.1. Safety Parameters  
Safety will be assessed by the following parameters:  
• Electrocardiograms (ECGs), clinical laboratory tests, physical examinations, the 
Columbia- Suicide Severity Rating Scale (C -SSRS), and vital signs, including supine 
and standing orthostatic blood pressure and heart rate. 
• Adverse events and concomitant medications will be evaluated throughout the course 
of the study. 
• The Gastroparesis Cardinal Symptom Index (GCSI) at Screening, and Visit 4 (Exit) 
only. 
12.2. Adverse Events  
12.2.1. Definition of Adverse Event  
An adverse event (adverse experience) is any untoward medical occurrence in a patient or clinical trial subject administered a medicinal product and which does not necessarily have to 
have a causal relationship with this treatment.  An adverse event can therefore be any unfavorable and unintended sign (eg, an abnormal laboratory finding), symptom, or disease 
temporally associated w ith the use of a medicinal product, whether or not considered related to 
the medicinal product. 
All AEs and any clinically significant physical examination findings, 12 -lead ECG 
abnormalities, or clinical laboratory measurements occurring during the study that were not 
present prior to administration of study medication and that continue at Study Exit should be 
followed and evaluated with additional tests, if necessary, until the AEs are medically stable or 
resolved.  Follow-up on these AEs should be recorded on the source documents and reported to 
Impax.  
12.2.2. Recording Adverse Events  
Elicit information about AEs with nonselective questions such as:  “Have you experienced any 
changes in your health status since your last visit?”  Encourage subjects to report AEs at onset.  
Record information for any AE that emerges from the time the subject signs the ICF until Study 
Exit.  
Monitor each subject closely for the development of AEs and record all such events on the AE page of the CRF.  Whenever possible, group signs and symptoms that constitutes a single diagnosis.  For example, cough, rhinitis, and sneezing might be grouped as upper respiratory 
infection. 
For each AE, record the onset date, severity, seriousness, relationship to study medication, date 
of resolution (or continuing), action taken, and outcome in the CRF.  The Investigator is to make 
a causality assessment (relationship to study medication) for every AE.  
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 38 of 112 12.2.3. Follow-up 
The Investigator must follow each AE until resolved or medically stable. 
12.2.4. Relationship to Study  Drug 
The Investigator documents his/her opinion of the relationship of the AE to the study medication 
as follows: 
• Not Related —the experience can be readily explained by the subject’s underlying 
medical condition or concomitant medications and no relations hip exists between the 
study medication and the experience.  
• Unlikely Related —the temporal relationship between the AE and the administration 
of the study medication is uncertain and it is likely that the AE can be explained by the subject’s medical condition or other therapies. 
• Possibly Related —there is some logical temporal relationship between the AE and 
the administration of the study medication and the experience is unlikely to be 
explained by the subject’s medical condition or other therapies. 
• Related —the temporal relationship is compelling between the administration of the 
study medication and the AE cannot be explained by the subject’s medical condition 
or other therapies. 
12.2.5. Assessment of Severity  
Grade each AE for severity and note in the description of the AE.  Determine the severity category of mild, moderate, or severe, as defined below, and enter the information on the AE page of the CRF. 
• Mild —causing no limitation of usual activities  
• Moderate— causing some limitation of usual activities  
• Severe—causi ng inability to carry out usual activities  
12.3. Serious Adverse Events  
12.3.1. Definition of Serious Adverse Event  
A serious adverse event (SAE) is any AE occurring at any dose that results in any of the following outcomes, regardless of relationship to the study medication: 
• Death  
• A life -threatening adverse drug experience  
• Inpatient hospitalization or prolongation of existing hospitalization  
• A persistent or significant disability/incapacity  
• A congenital anomaly/birth defect  
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 39 of 112 • Important medical events that may not result in death, be life- threatening, or require 
hospitalization may be considered an SAE when, based upon appropriate medical 
judgment, they may jeopardize the subject and may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition. 
12.3.2. Reporting Serious Adverse Events  
Any SAE that occurs from the time the subject signs an ICF until 30 days after taking the final 
dose of study medication must be reported by the investigative staff to the Sponsor or the 
Sponsor’s representative within 24 hours of knowledge of the event (s ee Study Contact 
Information ). 
An SAE form must be completed and sent to the Sponsor and/or the Sponsor’s representative.  All SAEs must also be recorded on the AE page of the CRF.  Additionally, all SAEs must be reported to the institutional review board (IRB) per the IRB’s requirements. 
Those SAEs that are considered both serious and unexpected and related to the study drug are 
subject to expedited reporting.  An “unexpected AE” is any AE where the nature or sev erity is 
not consistent with the current investigator brochure (IB) or if an IB is not required or available, 
the specificity or severity is not consistent with the provided risk information. 
Unexpected fatal or life- threatening SAEs related to the study d rug must be reported by the 
Sponsor to the appropriate regulatory authority in an expedited manner (ie, first report within 
7 days of first knowledge by the Sponsor).  The Sponsor will provide a final written report to that 
authority within 15 days of initial receipt of information on the event.  The Sponsor or the Sponsor’s representative will also inform all participating Investigators of the SAE.  
Unexpected SAEs that are not fatal or life -threatening must be reported by the Sponsor to the 
appropriate reg ulatory authority as soon as possible but no later than 15 calendar days after first 
knowledge of the SAE by the Sponsor.  The Sponsor or the Sponsor’s representative also 
informs all participating Investigators of the SAE.  
Subjects withdrawn from the study due to any SAE will be followed until the SAE is resolved or 
medically stable.  Record all SAEs, regardless of severity and whether or not related to the study 
medication, on the appropriate page of the CRF. 
The Investigator must determine whether the seriousness of the event warrants removal of the 
subject from the study.  He/she should, in any case, institute appropriate diagnostic and 
therapeutic measures and keep the subject under observation for as long as is medically 
indicated, or refer the subject  to appropriate health professionals. 
12.4. Pregnancy  
Any pregnancy that occurs from the time the subject signs an ICF until 30  days after taking the 
final dose of study medication must be reported within 24 hours to the Sponsor or the Sponsor’s representative and the subject should be terminated from the study.  All pregnancies will be followed through to delivery of the infant.  If the subject experiences a termination of the 
pregnancy, it should be reported as defined in Section  12.3.2. 
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 40 of 112 12.5. Other Safety Parameters and Related Information  
Additional safety parameters (laboratory tests, 12-lead ECGs, physical examinations, and vital 
signs), the C- SSRS, the GCSI,  and concomitant medications are collected as shown in the 
Schedule of Assessments in Section  8 and evaluated over the course of the study.  Clinical 
laboratory assessments are listed in Appendix C . 
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 41 of 112 13. STATISTICS  
13.1. Study Design and Sample Size Estimation  
This study is an open- label study in PD subjects.  All subjects who successfully complete 
IPX203- B16-02 are eligible to enroll in this study; it is estimated that approximately 300  subject s 
will be enrolled.  
13.2. Demographics and Baseline Characteristics  
Prestudy subject demographic s and baseline characteristics will be summarized to describe the 
subject population. 
13.3. Analysis of Efficacy/Clinical Utility Data  
The MDS -UPDRS Parts I to IV, PGI -S, CGI- S, PDQ -39, PDSS-2, PAS, NMSS, ZBI -12, and 
EMSQ  will be assessed at every visit.  The TS A will be assessed at every visit postbaseline.  
These data, along with the IPX203 dose and frequency information, will help characterize the 
clinical utility of IPX203.  These measures will be analyzed as follows: 
MDS -UPDRS  – The Total MDS -UPDRS and each of its components (Parts I through IV), and 
Parts II and III combined, as well as the changes from Baseline in these scores, will be 
summarized across each of the time points in the trial (Baseline/Visit 1, Month 3, Month 6, 
Month 9) to allow for clinical assessment of the continuing effect of IPX203 and of switching to IPX203 for those who were randomized to IR CD-LD.  For example, subjects randomized to 
IR CD-LD in Study IPX203- B16-02, will be examined for clinical improvement when switching 
to and following on IPX203 treatment.  Subjects randomized to IPX203 in Study IPX203- B16-
02 will be examined for maintaining clinical effect on IPX203. 
PGI-S – Subjects’ global impression of the severity of their PD and its treatment with IPX203 
will be summarized at M onths 3, 6, and 9 to assess the overall impact of IPX203 treatment over 
time.  The mean changes from Baseline/Visit 1 in PGI -S as well as the frequencies and 
percentages of each component of the PGI-S will be summarized over time.  The proportion of 
subjec ts with a PGI -S ≥ 4 and PGI-S ≥ 5 will also be summarized over time. 
CGI-S – Clinicians’ global impression of the severity of the subject’s PD and its treatment with 
IPX203 will be summarized at Months 3, 6, and 9 to assess the overall impact of IPX203 treatment over time.  The mean changes from Baseline/Visit 1 in CGI -S as well as the 
frequencies and percentages of each component of the CGI -S will be summarized over time.  
The proportion of subjects with a CGI-S ≥ 4 and CGI-S ≥ 5 will also be summarized over time.  
PDQ-39  – The PDQ -39 and its domains will be assessed in the same manner as the 
MDS -UPDRS.  
PAS – The PAS and its subscales (persistent anxiety, episodic anxiety, and avoidance behavior) 
will be assessed in the same manner as the MDS -UPDRS.  
NMSS  – The NMSS and individual domain will be assessed in the same manner as the 
MDS -UPDRS.  
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 42 of 112 PDSS-2  – The PDSS-2 (the total score and each component) will be summarized across all visits. 
TSA  – The TSA will be summarized across all visits.  
ZBI-12 – The ZBI-12 will be summarized across all visits . 
EMSQ  – The proportions of subjects with each of the early morning symptoms, the severity of 
each symptom, and whether the symptom improves after Parkinson’s medication will be 
summarized across all visits.  The change from baseline in total severity score will also be 
summarized across all visits.  
13.4. Analysis of Dosing Data  
Frequency of daily dosing and total daily dose of IPX203 at each visit after the baseline visit (Visit 1) will be summarized and compared against the baseline/Visit 1 daily dosing frequency.  Percentages of subjects who require up-titration and down- titration, as well as the number of 
titration steps, will be summarized.  
13.5. Population Analysis and Handling of Dropouts  
Assessments will be made on available data w ith no adjustments for dropouts. 
13.6. Analysis of Safety  
The safety analysis will include all subjects who received at least one dose of study medication.  Adverse events, supine and standing orthostatic vital signs, concomitant medications, 
electrocardiograms (ECGs), clinical laboratory tests, physical examinations, and the Columbia -
Suicide Severity Rating Scale (C -SSRS) will be evaluated throughout the course of the study. 
Adverse events will be collected and summarized both for the time in the open- label extension 
trial and the time of overall IPX203 exposure.  For summary and reporting purposes , “unlikely 
related ,” “possibly related ,” and “related” will be combined  and will be counted as “related .” 
Vital signs and ECGs will be summarized across the entire IPX203 exposure including 
information from the open-label extension and the prior IPX203- B16-02 study into which the 
subjects were enrolled.  
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 43 of 112 14. ADMINISTRATIVE PROCE DURES 
14.1. Guidelines for Good Clinical Practice  
This study will be conducted in accordance with pri nciples of Good Clinical Practice (GCP) as 
promulgated by the ICH.  Good Clinical Practice is an international ethical and scientific quality 
standard for designing, conducting, recording, and reporting trials that involve the participation of human subjects.  Compliance with this standard provides public assurance that the rights, 
safety, and well -being of human subjects are protected under current ethical principles, and that 
the clinical trial data are credible.  Current GCP standards may be found in ICH Guidance E6 
(Good Clinical Practice:  Consolidated Guidance).  This guidance describes the principles of 
GCP and the obligations of the institutional review board (IRB), the Investigator and the Sponsor 
in conducting this study in accordance with those pr inciples.  
14.2. Institutional Review Board Approval  
The review of this protocol by an IRB and the performance of all aspects of the study, including the methods used for obtaining informed consent, must be in accordance with principles 
enunciated in the ICH and GCP Guidelines and by the appropriate regulatory authorities. 
The Investigator is responsible for preparing documents for submission to the relevant IRB and 
obtaining written approval for this study.  Institutional Review Board approval must be obtained 
prior to the initiation of the study.  The Investigator’s continued participation in the study is 
contingent on renewing approval with the IRB at least annually. 
14.3. Informed Consent  
Site personnel should prepare an Informed Consent Form (ICF) incorporating the necessary 
elements of consent.  The ICF is to be approved by Impax prior to submission to the IRB.  The 
Investigator or his/her staff must explain the nature of the investigation and the risks involved to each subject prior to screening, and obtain a signed ICF.  The subject should also be informed 
that he/she is free to voluntarily withdraw from the study at any time.  
14.4. Study Monitoring  
Impax representatives or designees will conduct site visits to the investigational facilities for the 
purpose of monitoring the study.  The Investigator agrees to allow the monitor to inspect the drug storage area, study drug stocks, drug accountability records, subject charts and study source 
documents, and other records relevant to study conduct.  The Investigator must permi t access to 
such records if a regulatory or compliance audit is required. 
14.5. Protocol Amendments 
All amendments to the protocol must be documented in writing, reviewed and approved by the Sponsor and Investigator, and submitted to the IRB for approval prior t o implementation.  If the 
protocol amendment substantially alters the study design or potential risk to the subject, a new 
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 44 of 112 written ICF for continued participation in the study must be obtained from each subject affected 
by the change.  
14.6. Termination of Study  
The Sponsor has the right to terminate this study and remove all study material from the site at any time for medical or administrative reasons.  In this event, the Sponsor will endeavor to give 
adequate notice to allow safe withdrawal of subjects from the study.  
14.7. Case Report Forms  
Site personnel should collect and record data for the study as source documents, and transfer the 
data into the CRF. 
The Investigator must ensure that complete data for the clinical study are collected and 
accurately documented in  the appropriate sections of the CRF and adequately supported by the 
appropriate source documentation.  In addition, it is the Investigator’s responsibility to provide 
signatures where requested indicating concurrence with data in the CRF.  
14.8. Investigator’s F inal Conduct Report  
At the completion of the study, the Investigator must provide Impax a copy of the final conduct 
report that was submitted to their IRB, including a review of AEs.  
14.9. Records Retention  
International Conference on Harmonization, GCP, and US FDA guidelines require that essential 
documents be retained until at least 2 years after the last approval of a marketing application and 
until there are no pending or contemplated marketing applications, or at least 2 years have elapsed since the formal d iscontinuation of clinical development of the investigational product. 
However, the essential documents should be retained for a longer period if required by the applicable regulatory requirements or by an agreement with the Sponsor.  Records should never be destroyed without written approval from the Sponsor. 
If an Investigator leaves the institution, he/she must transfer responsibilities for record retention 
to another individual willing to accept them.  The Investigator must notify the Sponsor in writing of the transfer of study documents before the transfer of the study documents. 
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 45 of 112 15. PUBLICATION POLICY 
Study results may not be published without prior written approval from Impax. 
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 46 of 112 16. LIST OF REFERENCES 
Bédard M, Molloy DW, Squire L, Dubois S, Lever JA, O'Donnell M. The Zarit Burden 
Interview: a new short version and screening version. Gerontologist. 2001;41(5):652-7. 
Blanchet PJ, Calon F, Martel JC, et al. Continuous administration decreases and pulsatile 
administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in 
MPTP -exposed monkeys. J Pharmacol Exp Ther. 1995;272:854-859. 
Engber TM, Susel Z, Juncos JL, Chase TN. Continuous and intermittent levodopa differentially 
affect rotation induced by D-1 and D-2 dopamine agonists. European Journal of Pharmacology. 
1989;168:291-298. 
Fahn S. Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L 
DOPA. Arch Neurol. 1999 May;56(5):529-35. 
Food and Drug Administration 2003.  Guidance for Industry.  Bioavailability and 
Bioequivalence Studies for Orally Administered Drug Products — General Considerations.  U.S. Department of Health and Human Services.  Food and Drug Administration. Center for Drug 
Evaluation and Research (CDER). March 2003. 
Hagell P, Alvariza A, Wester gren A, Årestedt K. Assessment of burden among f amily caregivers 
of people with Parkinson's disease using the Zarit Burden  Interview. J Pain Symptom Manage. 
2017;53(2):272-278. Juncos JL, Engber TM, Raisman R, et al. Continuous and intermittent levodopa di fferentially 
affect basal ganglia function. Ann Neurol. 1989;25:473-478. 
Kurlan R, Rothfield KP, Woodward WR, Nutt JG, Miller C, Lichter D, et al. Erratic gastric 
emptying of levodopa may cause “random” fluctuations of parkinsonian mobility. Neurology. 1988;38(3):419-21. 
Melamed E, Bitton V, Zelig O. Delayed onset of responses to single doses of L-dopa in 
parkinsonian fluctuators on long- term L -dopa therapy. Clin Neuropharmacol. 1986;9(2):182-8. 
Mizuno Y. Where do we stand in the treatment of Parkinson's disease? Neurology. 2007;254:13-
18. 
Nilsson D, Nyholm D, Aquilonius S-M. Duodenal levodopa infusion in Parkinson's disease --
long-term experience. Acta Neurologica Scandinavica. 2001;104:343-348. 
Nyholm D, Nilsson Remahl AI, Dizdar N, et al. Duodenal levodopa infusion monotherapy vs 
oral polypharmacy in advanced Parkinson disease. Neurology. 2005;64:216-223. 
Sinemet (Carbidopa-Levodopa) Tablets Prescribing Information. Whitehouse Station, NJ: 
Manufactured by Merck & Co., Inc.; Marketed by Bristol-Myers Squibb Company; 2013. 
Stocchi F, Quinn NP, Barbato L, Patsalos PN, O’Connel MT, Ruggieri S, et al. Comparison 
between a fast and a slow release preparation of levodopa and a combination of the two:  a 
clinical and pharmacokinetic study. Clinical Neuropharmacol. 1 994;17(1):38-44. 
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 47 of 112 Stocchi F, Vacca L, et al. Intermittent vs continuous levodopa administration in patients with 
advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol. 2005:62(6):905-910. 
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 48 of 112 17. APPENDICES  
 
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 49 of 112 APPENDIX A. RECOMMENDATIONS FOR IPX203  DOSING 
Subjects will be initially started on the final IPX203 dosing regimen that was determined during 
the IPX203 dose conversion period of Study IPX203- B16-02.  Investigators are permitted to 
adjust the dosing regimen of IPX203 during this study to achieve the optimal balance of efficacy 
and safety and any  dosing changes will be recorded  at the study visit. 
1. It is recommended that the subject takes IPX203 doses approximately every 8 hours apart (for example, a subject may take IPX203 at 6 AM, 2 PM, and 10 PM)
 with the exception 
that subjects who converted from a total daily dose of less than 125-500 mg IR CD- LD may 
take IPX203 every 12 hours .  Some subjects may benefit from a shorter or longer dosing 
interval.  The dosing interval may vary but should not be more frequent than every 6 hours. 
2. The Investigator ( or his/her staff ) is advised to be in telephone contact with the subject, 
especially during the initial weeks of this study, to assess the need for dosage adjustment 
with the goal of minimizing “Off” time without causing troublesome dyskinesia or other 
dopaminergic side effects.  Calls to the subject can be reduced when the subject reaches an acceptable stable dosing regimen. 
3. If dose adjustment is necessary, consider the following options recognizing that the 
number of capsules at each dose may be varied to achieve an optimal response. 
a. If turning “On” is slow following the first morning dose, consider taking the morning 
IPX203 dose in the fasted state and/or increasing the dose by one capsule (35-140 mg IPX203 CD- LD).  
b. If turning “On” is slow later in the day or to reduce “end- of-dose” “Off” time, 
consider increasing the dose by one capsule (35 -140 mg IPX203 CD- LD) before 
reducing the dosing interval. 
c. In case of troublesome dyskinesias,  consider reducing the dose by one capsule 
(35-140 mg IPX203 CD- LD) prior to increasing the dosing interval.  
4. Initially, all subjects will be dispensed 2 capsule dosage strengths, one of which will be 
the 35-140 mg IPX203 CD- LD capsules.  Following dose regimen stabilization, up to 
2 capsule dosage strengths may be dispensed from those available (35-140 mg, 52.5-210 
mg, 70-280 mg, and 87.5-350 mg  IPX203 CD -LD) 
 
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 50 of 112 APPENDIX B.  COLUMBIA-SUICIDE SEVERITY RATING SCALE 
(C-SSRS)  
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 51 of 112 
  
  
 
   
  
                
      
 
                   
                
              
                  
                  
                 
                    
            
                  
          
         
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 52 of 112 
  
                                               
     
                        
                
  
   
     
                        
         
           
   
             
                            
                         
                            
          
   
            
                            
       
               
   
         
                        
                        
  
   
   
                       
      
 
    
     
 
        
                         
 
          
            
               
      
 
               
               
            
              
 
                      
    
                 
            
          
   
                          
                        
        
                       
                    
                       
              
    
                
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 53 of 112  
 
   
                 
  
                               
                                                              
     
                        
                            
                     
      
       
            
     
          
            
           
              
                      
            
   
  
         
  
                        
 
                           
                          
                             
                                          
   
                           
                                            
     
    
    
                        
                       
                       
        
   
    
        
  
   
  
      
 
 
     
            
            
                   
                   
             
                    
             
  
        
                       
                            
   
         
              
            
               
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories, LLC  
 
Page 54 of 112 APPENDIX C. CLINICAL LABORATORY STUDIES  
 
HEMATOLOGY  
hemoglobin 
hematocrit  
red blood cell count white blood cell count % neutrophils % lymphocytes % monocytes 
% basophils 
% eosinophils absolute neutrophils absolute lymphocytes absolute monocytes 
absolute basophils 
absolute eosinophils platelet count  
CHEMISTRY  
sodium potassium 
chloride 
carbon dioxide blood urea nitrogen (BUN) 
creatinine  
glucose calcium  
phosphorous albumin  
total protein  
uric acid  
total bilirubin  
direct bilirubin  indirect bilirubin  
alkaline phosphatase alanine aminotransferase 
(ALT, SGPT)  
aspartate aminotransferase 
(AST, SGOT)  
creatine phosphokinase 
lactate dehydrogenase  
URINALYSIS  
pH 
specific gravity  
blood 
glucose ketones 
microscopic exam (RBC 
and WBC, only when indicated)  leukocyte esterase  
protein
 
PREGNANCY TES T 
Urine pregnancy test (to be completed on site) for female subjects of childbearing potential.  
 
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 55 of 112 APPENDIX D. MOVEMENT DISORDERS SOCIETY VERSION OF TH E 
UNIFIED PARKINSON’S DISEASE RATING SCALE  
(MDS-UPDRS)  
 
  
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 56 of 112 
     
 
      
          
         
   
   
           
                         
  
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 57 of 112 
  
             
          
               
            
              
 
       
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 58 of 112 
 
               
                
               
                   
                 
              
              
            
   
                 
                
                   
                
                  
                
                    
                  
                    
                      
               
      
       
    
         
            
          
            
          
        
         
     
      
    
      
    
  
  
   
                  
                       
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 59 of 112 
          
                
                   
                 
       
  
           
                     
 
                     
   
                      
                   
  
                  
     
                  
                 
               
                
                  
                    
 
          
        
                   
                     
   
                    
                        
                  
        
                    
         
                
    
                             
      
                         
      
                     
    
 
               
            
                      
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 60 of 112 
  
          
       
    
           
                       
          
         
                   
                        
        
   
              
              
           
               
               
              
  
     
           
           
           
           
               
      
              
   
 
               
                            
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 61 of 112 
    
 
           
            
 
             
               
       
                 
                 
 
  
       
           
 
           
 
        
       
   
              
               
             
                  
                       
                  
     
  
     
               
             
 
             
     
              
        
              
  
 
 
                 
                           
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 62 of 112 
   
             
                  
      
                 
                       
                  
  
     
  
                 
            
        
      
            
                
     
              
 
  
            
                 
               
 
                
                 
    
  
             
    
        
          
          
 
 
                 
                           
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 63 of 112 
      
             
             
      
     
            
           
               
              
                 
 
              
                   
              
            
  
     
     
         
 
               
   
                
   
              
            
   
 
                
              
              
                 
                           
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 64 of 112 
  
 
           
                
                    
               
   
                
                  
                
     
             
            
  
                
                
        
          
           
                 
                           
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 65 of 112 
          
   
                
              
  
  
    
          
      
          
  
              
            
            
   
             
  
     
           
            
     
             
      
               
     
 
 
                 
                           
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 66 of 112 
 
     
               
   
     
               
   
              
   
               
        
             
 
   
               
            
      
             
       
           
       
              
 
  
               
  
                 
                           
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 67 of 112 
   
             
 
  
  
  
    
            
           
 
          
  
              
          
 
             
 
     
                 
   
  
       
           
    
 
                 
        
               
   
            
                 
                           
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 68 of 112 
  
                
   
  
    
          
     
            
 
              
          
            
          
  
           
  
       
 
            
      
            
    
   
           
          
            
 
 
                 
                           
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 69 of 112 
 
    
               
     
       
           
              
                     
                
     
    
              
                 
    
    
              
             
 
                           
   
           
            
 
                 
                           
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 70 of 112 
   
              
             
    
  
  
       
               
      
             
  
        
              
           
  
              
                
   
  
       
         
              
 
         
            
 
 
                 
                           
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 71 of 112 
 
  
                
        
    
       
                           
         
             
  
            
       
               
           
          
         
      
               
     
       
            
          
             
             
                 
                           
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 72 of 112 
 
    
             
       
                
               
  
            
             
  
           
           
             
  
            
            
 
            
          
                  
  
       
                 
                
                  
  
           
                 
                           
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 73 of 112 
    
             
  
  
       
               
              
  
              
           
 
              
 
  
                
         
  
  
       
              
            
  
         
     
           
 
                
            
    
                
      
 
 
               
                 
                 
            
                 
                           
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 74 of 112 
    
                   
        
                    
          
                 
      
                
                 
               
                
                 
                      
       
   
          
                  
               
                
                   
  
                      
   
      
                 
              
         
                  
                   
           
          
                
                           
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 75 of 112 
  
              
                
            
         
  
  
     
             
              
    
                 
  
          
   
                
             
     
  
  
     
          
            
            
      
                 
                  
 
 
                 
                           
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 76 of 112 
  
                 
                
                 
                 
                
  
              
  
  
    
      
             
 
              
  
              
 
   
                
                   
                
      
  
  
    
                
            
       
                
        
                 
            
      
               
  
  
  
  
  
  
  
  
                 
                           
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 77 of 112 
   
               
                    
                     
                      
              
  
  
  
    
                
            
     
               
        
                 
            
        
               
 
     
               
                    
                
      
             
  
  
  
    
                
            
     
               
        
                 
            
        
               
  
  
  
 
 
 
                 
                           
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 78 of 112 
   
                  
                 
                   
                   
      
    
                 
 
          
      
  
                 
        
               
             
       
  
                
 
                
                 
                    
                    
              
  
  
    
               
            
     
                
        
                
            
       
 
              
   
 
 
 
 
 
 
                 
                           
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 79 of 112 
 
    
                  
                     
                    
                    
                 
                     
                  
 
          
                
                 
  
           
                    
          
       
  
                
                 
                  
               
                 
            
    
        
          
               
 
            
                 
                           
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 80 of 112 
    
               
             
                   
 
  
  
  
  
    
             
            
 
             
           
  
    
 
      
   
              
                  
   
            
                   
        
           
                
                
                  
                  
                  
                  
                
                  
                  
             
  
  
  
  
          
      
        
             
 
              
   
 
 
                 
                           
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 81 of 112 
  
                
                 
                   
           
  
  
    
           
             
        
              
        
           
       
             
                
              
           
    
          
          
          
          
      
                
                 
                    
                 
 
  
  
  
  
    
          
            
            
         
 
 
  
  
                 
                           
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 82 of 112 
 
      
                
              
               
                 
                
                
    
             
              
                         
 
    
                 
                   
                
                    
              
                       
                   
  
                
            
   
     
        
                     
 
         
        
        
             
             
        
                 
                           
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 83 of 112 
     
                 
                  
                 
  
    
  
  
  
             
           
           
            
      
         
          
    
  
    
           
    
            
      
          
        
 
 
                 
                           
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 84 of 112 
    
                 
              
                 
                     
                    
                    
                 
     
    
               
                 
  
        
           
      
               
    
                   
                
             
              
               
      
     
                
                
                  
                  
              
    
                  
                
                   
                  
                    
               
                  
    
    
       
           
            
              
 
                 
                            
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 85 of 112 
     
              
                
               
                 
                
    
  
  
  
  
              
            
          
         
  
          
             
            
   
             
          
  
   
       
                
                   
                    
                  
                  
             
              
                
                   
                   
                     
          
     
       
       
           
           
     
 
 
                 
                            
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 86 of 112 
     
               
              
                      
                     
               
         
                
                  
                  
                
  
  
  
  
              
  
            
           
     
           
           
     
             
    
        
        
             
            
     
     
               
                 
                  
                   
                
          
                
                   
                   
                   
     
     
              
           
           
          
 
 
                 
                           
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 87 of 112 
   
    
              
               
                
         
                 
                 
                    
                      
  
  
        
       
        
        
         
    
     
      
        
                  
                      
                     
                     
         
                 
                           
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 88 of 112  
    
    
           
     
     
        
       
       
      
        
      
                
       
       
         
       
     
         
     
    
       
        
        
       
      
      
      
          
        
      
         
        
         
            
        
             
            
         
      
        
         
     
            
                            
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 89 of 112 APPENDIX E.  PATIENT GLOBAL IMPRESSION OF SEVERITY (PGI- S) 
 
The subject will independently rate the following question of Patient Global Impression of 
Severity (PGI -S) based on his/her overall impression of the study medication at Visit 2 
(Month 3), Visit 3 (Month 6), and Visit 4 (Month 9) or early discontinuation. 
 
Patient Global Impression of Severity Scale 
 
Severity of Illness  
 
Considering the severity of your Parkinson’s disease, how severe is your condition at this time? 
 
 Severity Score:  
 
 1  2  3  4  5  6  7 
Normal,  
not at all ill  Borderline 
ill Mildly  
ill Moderately  
ill Markedly  
ill Severely  
ill  
Extremely 
severely ill  
 
 
 
 
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 90 of 112 APPENDIX F. CLINICAL GLOBAL IMPRESSION OF SEVERITY 
(CGI-S) 
 
The Investigator will independently rate the following question of Clinical Global Impression of 
Severity (CGI -S) based on his/her overall impression of the study medication at Visit 2 
(Month 3), Visit 3 (Month 6), and Visit 4 (Month 9) or early discontinuation. 
 
Clinical Global Impression of Severity Scale  
 
Severity o f Illness 
 
Considering your total clinical experience with this particular population,  
how ill is the patient at this time?  
 
 
Severity Score:  
 
 1  2  3  4  5  6  7 
Normal,  
not at all ill  Borderline 
ill Mildly  
ill Moderately  
ill Markedly  
ill Severely  
ill  
Among the 
most 
extremely ill 
of subjects 
 
 
  
 
  
Guy W. ECDEU assessment manual for psychopharmacology publication; ADM, 76-338. 
Washington DC, US. Department of health, education and welfare, 1976. 
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 91 of 112 APPENDIX G.  39-ITEM PARKINSON’S DIS EASE QUESTIONNAIRE 
(PDQ-39) 
 
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 92 of 112 
       
     
         
       
 
         
                 
     
          
   
           
            
              
                  
             
                
           
       
           
                    
      
       
 
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 93 of 112 
     
         
       
 
         
       
       
                
           
         
            
          
            
              
        
          
           
       
           
                    
      
       
 
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 94 of 112 
     
         
       
    
        
        
       
         
             
             
             
            
           
           
       
            
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
                    
      
    
    
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 95 of 112 
     
         
       
    
     
      
       
      
      
      
     
  
    
    
     
      
     
 
    
     
 
        
   
 
  
   
   
 
  
   
 
  
   
           
       
            
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
                    
      
    
    
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 96 of 112  
     
        
       
     
            
               
           
           
      
           
                   
      
      
 
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 97 of 112 APPENDIX H.  GASTROPARESIS CARDINAL SYMPTOM INDEX 
(GCSI) 
 
 
 
 
               
              
   
              
                 
                   
                    
     
             
      
 
       
             
  
               
       
        
             
           
         
               
           
                   
                 
    
                     
                 
         
              
 
       
 
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 98 of 112 APPENDIX I. NON-MOTOR SYMPTOM ASSESSMENT SCALE FOR 
PARKINSON’S DISEASE (NMSS) 
 
  
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 99 of 112  
 
       
         
           
                      
               
                        
                
             
     
            
   
          
 
   
             
            
               
          
                  
         
 
    
         
                
             
              
              
            
       
 
    
             
              
        
        
        
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 100 of 112  
   
 
   
                    
                           
                    
  
    
            
          
       
          
  
   
            
                
                    
    
         
           
           
  
   
             
                 
                
                 
               
  
  
        
    
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 101 of 112 APPENDIX J. PARKINSON’S DISEASE SLEEP SCALE-2 (PDSS -2) 
  
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 102 of 112  
 
Trenkwalder C, Kohnen R, Högl B, Metta V, Sixel -Döring F, Frauscher  B, Hülsmann J, Martinez -Martin P, 
Chaudhuri KR. Parkinson’s disease sleep scale --validation of the revised version PDSS -2. Mov Disord. 
2011;26(4):644- 52 
     
               
      
  
 
 
 
         
        
        
      
   
        
    
       
    
      
   
        
         
        
         
      
     
      
             
           
       
         
       
          
              
        
        
        
 
         
         
         
        
         
       
          
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           
          
           
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 103 of 112 APPENDIX K.  PARKINSON ANXIETY SCALE (PAS)  
 
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 104 of 112 
       
   
        
              
     
      
     
    
    
     
     
      
     
    
    
     
     
      
     
    
    
     
      
      
     
    
    
     
          
      
     
    
    
     
                 
              
       
 
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 105 of 112 
   
        
             
     
  
  
  
  
   
    
  
  
  
  
   
              
  
  
  
  
   
     
  
  
  
  
   
                 
              
       
 
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 106 of 112  
 
  
   
        
                
              
  
      
  
  
  
  
   
              
          
  
  
  
  
   
      
       
   
  
  
  
  
   
                 
              
       
 
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 107 of 112 APPENDIX L.  TREATMENT SATISFACTION ASSESSMENT (TSA)  
 
The subject independently answers the following question of treatment satisfaction based on 
his/her overall impression of the study medication at Visits 2, 3, and 4. 
 
Treatment Satisfaction Assessment:  
In general, how satisfied are you with your current Parkinson’s di sease medication?  
 1  2  3  4  5  6  7 
Very much  
dissatisfied  Very  
dissatisfied  Somewhat 
dissatisfied  Neither 
satisfied nor 
dissatisfied  Somewhat 
satisfied  Very  
satisfied  Very much  
satisfied  
 
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 108 of 112 APPENDIX M. 12-ITEM ZARIT BURDEN INTERVIEW (ZBI-12) 
 
 
  
   
              
                
              
 
        
      
       
 
      
       
     
   
        
   
       
    
     
     
       
    
        
    
    
        
       
    
        
     
    
        
      
  
      
      
       
     
        
      
 
         
 
   
  
        
  
     
     
     
     
     
     
     
     
     
     
     
     
    
    
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 109 of 112 APPENDIX N. EARLY MORNING SYMPTOMS QUE STIONNAIRE 
(EMSQ) 
 
Questions:  
1. Over the past week, when you awakened in the morning for the day from your night- time 
sleep, on how many days did you experience each of the following symptoms? 
a. Tremor    0   1-3   4-7 
b. Stiffness    0   1-3   4-7 
c. Slowness   0   1-3   4-7 
d. Walking/Turning   0   1-3   4-7 
e. Loss of Balance    0   1-3   4-7 
f. Urinary Control   0   1-3   4-7 
g. Anxious Feelings   0   1-3   4-7 
h. Too Much Saliva   0   1-3   4-7 
i. Depressed or Sad Feelings    0   1-3   4-7 
j. Bodily Discomfort or Pain   0   1-3   4-7 
  
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 110 of 112  
2. If you experienced any symptom in the question (Q.1) above on at least one day over the 
past week , indicate for this symptom (or for these symptoms) the severity to which this 
symptom impaired your morning activities and social interactions using the severity 
definitions below : 
a. Tremor   Mild   Moderate   Severe  
b. Stiffness   Mild   Moderate   Severe  
c. Slowness  Mild   Moderate   Severe  
d. Walking/Turning  Mild   Moderate   Severe  
e. Loss of Balance   Mild   Moderate   Severe  
f. Urinary Control  Mild   Moderate   Severe  
g. Anxious Feelings  Mild   Moderate   Severe  
h. Too Much Saliva  Mild   Moderate   Severe  
i. Depressed or Sad Feelings   Mild   Moderate   Severe  
j. Bodily Discomfort or Pain  Mild   Moderate   Severe  
 Severity Definitions
: 
Mild :  Causes mild impact on one or more early morning functions  but I am usually able to 
perform most morning activities and participate in most social interactions.  
Moderate :  Impacts one or more early morning functions to the point that I am usually not able 
to perform some morning activities and/or participate in some social interactions.  
Severe :  Impacts one or more early morning functions to the point that I am usually not able to 
perform most morning activities and/or participate in most social interactions.  
  
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 111 of 112  
3. Which of the early morning symptoms  (if any) that you identified above and assessed 
severity in Q.2 above improved after taking a first morning dose of your Parkinson’s 
medication(s)?  For each symptom, i ndicate “Y ES” improved  or “NO” did not improv e.  If 
you did not experience the symptom (ie, answered 0 in Q.1 above), indicate “Did not 
experience”.  
a. Tremor    Yes    No   Did not experience 
b. Stiffness    Yes    No   Did not experience 
c. Slowness   Yes    No   Did not experience 
d. Walking/Turning   Yes    No   Did not experience 
e. Loss of Balance    Yes    No   Did not experience 
f. Urinary Control   Yes    No   Did not experience 
g. Anxious Feelings   Yes    No   Did not experience 
h. Too Much Saliva   Yes    No   Did not experience 
i. Depressed or Sad Feelings    Yes    No   Did not experience 
j. Bodily Discomfort or Pain   Yes    No   Did not experience 
 
  
Protocol No. IPX203- B16-03 CONFIDENTIAL  
Amendment 2: 26 November 2018 Impax Laboratories,  LLC  
 
Page 112 of 112 APPENDIX O.  COMPONENTS OF IPX203 
 
Active ingredients :  carbidopa and levodopa 
 
Inactive ingredients:   The excipients in th e IPX203 investigational formulations include the 
following: microcrystalline cellulose, mannitol, amino methacrylate copolymer, sodium lauryl 
sulfate, methacrylic acid copolymer Type A, copovidone, cellulose acetate, croscarmellose sodium, talc, triethyl citrate, povidone, magnesium stearate.  All these excipients are United 
States Pharmacopeia and National Formulary.  The investigational formulations will be enclosed in hard gelatin capsules. 
 